IDH2 and astrocytoma (excluding glioblastoma): Of note, we found that CDK4/6 inhibitor selectively suppressed cell viability of phospho-Rb-upregulated, recurrent cells, further supporting the critical role of cell cycle deregulation in progression in IDH2-mutant astrocytoma.